Statins and cardiovascular disease outcomes: before and during the COVID-19 pandemic (SCOBAC): meta-analysis and systematic review of large populations
DOI:
https://doi.org/10.36216/jpd.v7i1.204Keywords:
Cardiovascular Disease, COVID-19 MACEs, Mortality, statinsAbstract
Background: Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide, both due to heart and vascular disease. In Indonesia alone, 470,000 deaths are estimated each year due to CVD. Based on the latest guideline, statins are highly recommended in the prevention of CVD.
Objective: To assess the role of statins in reducing CVD rates, and all-cause mortality, before and during the COVID-19 pandemic respectively.
Methods: Literature search was performed from 1994 – 2021. Data extraction was in the form of Major Adverse Cardiac Events (MACEs) before the pandemic, and all-cause mortality, before and during the COVID-19 pandemic. Literature of medical database extracted based on inclusion and exclusion criteria. The research analyzed two study designs: clinical trials for pre-pandemic and observational studies for pandemics.
Results: After critical appraisal, 23 clinical trials and 9 observational studies were included in the data analysis. Statins played a role in reducing MACEs before the pandemic (OR: 0.62, p < 0.05, 95% CI 0.60 – 0.74, I2 = 91%). However, there was no significance between the groups receiving statins and those without statins in reducing mortality during the pandemic (RR: 0.97, p > 0.05, 95% CI 0.90 – 1.04).
Conclusion: Statins have been shown to statistically reduce mortality before the COVID-19 pandemic and further studies are needed during the pandemic. Government policies need to consider the lack of screening for dyslipidemia and appropriate statin treatment in the primary care setting, especially during the pandemic.
Downloads
References
Zhai C, Hou K, Li R, Hu Y, Zhang J, Zhang Y, et al. Efficacy of statin treatment based on cardiovascular outcomes in elderly patients: a standard meta-analysis and Bayesian network analysis. Journal of International Medical Research. 2020 Jun;48(6):030006052092634.
Hussain MA, al Mamun A, Peters SA, Woodward M, Huxley RR. The burden of cardiovascular disease attributable to major modifiable risk factors in Indonesia. J Epidemiol. 2016;26(10):515–521.
Hariyadi D, Hendriyani H, Nindrea RD. A path model of factors associated with cardiovascular disease in West Borneo: analysis of Indonesian Basic Health Survey 2018. Systematic Reviews in Pharmacy. 2021;12(12):3803–3809.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111–188.
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–3337.
Garg H, Khanna P. Covid and cholesterol (C&C): Something to worry about or much ado about nothing?. Trends in Anaesthesia and Critical Care. 2021;36:39–40.
Wang H, Yuan Z, Pavel MA, Jablonski SM, Jablonski J, Hobson R, et al. The role of high cholesterol in age-related COVID19 lethality. bioRxiv. 2021; 2020.05.09.086249.
Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17(9):543–558.
Bifulco M, Gazzerro P. Statins in coronavirus outbreak: It's time for experimental and clinical studies. Pharmacol Res. 2020;156:104803.
Baran Ç, Durdu S, Dalva K, Zaim Ç, Dogan A, Ocakoglu G, et al. Effects of preoperative short term use of atorvastatin on endothelial progenitor cells after coronary surgery: a randomized, controlled trial. Stem Cell Rev Rep. 2012;8(3):963–971.
Natsuaki M, Nakagawa Y, Morimoto T, Ono K, Shizuta S, Furukawa Y, et al. Impact of statin therapy on late target lesion revascularization after sirolimus-eluting stent implantation (from the CREDO-Kyoto Registry Cohort-2). American Journal of Cardiology. 2012;109(10):1387–1396.
Ramos R, García-Gil M, Comas-Cufí M, Quesada M, Marrugat J, Elosua R, et al. Statins for Prevention of Cardiovascular Events in a Low-Risk Population With Low Ankle Brachial Index. J Am Coll Cardiol. 2016;67(6):630-640.
Trenk D, Hochholzer W, Frundi D, Stratz C, Valina CM, Bestehorn HP, et al. Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thromb Haemost. 2008;99(1):174–181.
Vigen C, Hodis HN, Selzer RH, Mahrer PR, Mack WJ. Relation of progression of coronary artery atherosclerosis to risk of cardiovascular events (from the Monitored Atherosclerosis Regression Study). American Journal of Cardiology. 2005;95(11):1277–1282.
Owen OG. The collaborative atorvastatin diabetes study: preliminary results. Int J Clin Pract. 2005;59(1):121–123.
Agema WRP, Jukema JW, de Maat MPM, Zwinderman AH, Kastelein JJP, Rabelink TJ, et al. Pharmacogenetics of the CD14 endotoxin receptor polymorphism and progression of coronary atherosclerosis. Thromb Haemost. 2004;91(05):986–990.
Anderssen SA, Hjelstuen AK, Hjermann I, Bjerkan K, Holme I. Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis. 2005;178(2):387–397.
Lindholm LH. Changes in cardiovascular risk factors by combined pharmacological and nonpharmacological strategies : the main results of the CELL Study. Journal of Internal Medicine. J Intern Med. 1996;240(1):13-22.
Beishuizen ED, Van De Ree MA, Jukema JW, Tamsma JT, Carel J, Van Der Vijver M, et al. Two-Year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. Diabetes Care. 2004;27(12):2887-2892.
Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther. 2003;25(4):1107-1122.
Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, et al; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297(12):1344-1353.
Furberg CD, Adams HP, Applegate WB, Byington RP, Espeland MA, Hartwell T, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation. 1994;90(4):1679–1687.
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). The Lancet. 1994;344(8934):1383-1389.
Salonen R, Nyyssönen K, Porkkala E, Rummukainen J, Belder R, Park JS, et al. Kuopio Atherosclerosis Prevention Study (KAPS). Circulation. 1995;92(7):1758–1764.
Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New England Journal of Medicine. 1995;333(20):1301–1308.
Mercuri M, Bond MG, Sirtori CR, Veglia F, Crepaldi G, Saverio Feruglio F, et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: The Carotid Atherosclerosis Italian Ultrasound Study. Am J Med. 1996;101(6):627–634.
Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New England Journal of Medicine. 1996;335(14):1001–1009.
Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998;279(20):1615.
Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349–1357.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. The Lancet. 2002;360(9326):7–22.
Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. The Lancet. 2002;360(9346):1623–1630.
Asselbergs FW, Diercks GFH, Hillege HL, van Boven AJ, Janssen WMT, Voors AA, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110(18):2809–2816.
Zanchetti A, Crepaldi G, Bond MG, Gallus G, Veglia F, Mancia G, et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis. Stroke. 2004;35(12):2807–2812.
Lemos PA, Serruys PW, de Feyter P, Mercado NF, Goedhart D, Saia F, et al. Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). Am J Cardiol. 2005;95(4):445–451.
Stegmayr BG, Brännström M, Bucht S, Crougneau V, Dimeny E, Ekspong A, et al. Low-dose atorvastatin in severe chronic kidney disease patients: A randomized, controlled endpoint study. Scand J Urol Nephrol. 2005;39(6):489–497.
Knopp RH, d’Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes. Diabetes Care. 2006;29(7):1478–1485.
Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. The Lancet. 2006;368(9542):1155–1163.
Neil HAW, DeMicco DA, Luo D, Betteridge DJ, Colhoun HM, Durrington PN, et al. Analysis of efficacy and safety in patients aged 65–75 years at randomization. Diabetes Care. 2006;29(11):2378–2384.
Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549–559.
Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JGF, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248–2261.
Sever PS, Poulter NR, Dahlof B, Wedel H, Beevers G, Caulfield M, et al. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J. 2008;29(4):499–508.
Soveri I, Abedini S, Holdaas H, Jardine A, Eriksson N, Fellström B. Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clin Transplant. 2009;23(6):914–920.
Glynn RJ. Rosuvastatin for primary prevention in older persons with elevated c-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med. 2010;152(8):488.
Han BH, Sutin D, Williamson JD, Davis BR, Piller LB, Pervin H, et al. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults. JAMA Intern Med. 2017;177(7):955.
Alamdari NM, Afaghi S, Rahimi FS, Tarki FE, Tavana S, Zali A, et al. Mortality risk factors among hospitalized COVID-19 patients in a major referral center in Iran. Tohoku J Exp Med. 2020;252(1):73–84.
Butt JH, Gerds TA, Schou M, Kragholm K, Phelps M, Havers-Borgersen E, et al. Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19): a nationwide cohort study. BMJ Open. 2020;10(12):e044421.
Gupta A, Madhavan MV, Poterucha TJ, DeFilippis EM, Hennessey JA, Redfors B, et al. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Res Sq. 2020;rs.3.rs-56210.
Krishnan S, Patel K, Desai R, Sule A, Paik P, Miller A, et al. Clinical comorbidities, characteristics, and outcomes of mechanically ventilated patients in the State of Michigan with SARS-CoV-2 pneumonia. J Clin Anesth. 2020;67:110005.
Masana L, Correig E, Rodríguez-Borjabad C, Anoro E, Arroyo JA, Jericó C, et al. Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients. Eur Heart J Cardiovasc Pharmacother. 2022;8(2):157–164.
Nicholson CJ, Wooster L, Sigurslid HH, Li RH, Jiang W, Tian W, et al. Estimating risk of mechanical ventilation and in-hospital mortality among adult COVID-19 patients admitted to Mass General Brigham: The VICE and DICE scores. EClinicalMedicine. 2021;33:100765.
Saeed O, Castagna F, Agalliu I, Xue X, Patel SR, Rochlani Y, et al. Statin use and in‐hospital mortality in patients with diabetes mellitus and COVID‐19. J Am Heart Assoc. 2020;9(24):e018475.
Song SL, Hays SB, Panton CE, Mylona EK, Kalligeros M, Shehadeh F, et al. Statin use is associated with decreased risk of invasive mechanical ventilation in COVID-19 patients: a preliminary study. Pathogens. 2020;9(9):759.
Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, Yuan Y, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020;32(2):176-187.e4.
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. 2019: John Wiley & Sons; The Cochrane Collaboration.
Aronow WS. Statins reduce cardiovascular events in primary and secondary prevention trials without causing an increase in carcinoma. J Am Geriatr Soc. 2009;57(10):1942–1943.
Yebyo HG, Aschmann HE, Puhan MA. Statins for primary prevention of cardiovascular disease. Ann Intern Med. 2019;171(1):74.
Kow CS, Hasan SS. The association between the use of statins and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2022;22(2):167-181.
Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, Yuan Y, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020;32(2):176-187.e4.
Kow CS, Hasan SS. Meta-analysis of effect of statins in patients with COVID-19. Am J Cardiol. 2020;134:153–155.
Atmosudigdo IS, Lim MA, Radi B, Henrina J, Yonas E, Vania R, et al. Dyslipidemia increases the risk of severe COVID-19: a systematic review, meta-analysis, and meta-regression. Clin Med Insights Endocrinol Diabetes. 2021;14:117955142199067.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Jurnal Penyakit Dalam Udayana
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
